1887
banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
/content/aapm/journal/medphys/26/10/10.1118/1.598721
1.
1.A. V. D’Amico and C. N. Coleman, “Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out,” J. Clin. Oncol. 14, 304315 (1996).
2.
2.W. F. Whitmore, B. Hilaris, and H. Grabstald, “Retropubic implantation to iodine-125 in the treatment of prostatic cancer,” J. Urol. (Baltimore) 108, 918920 (1972).
3.
3.L. L. Anderson, “Spacing nomograph for interstitial implants of seeds,” Med. Phys. 3, 4851 (1976).
4.
4.L. L. Anderson, J. V. Moni, and L. B. Harrison, “A nomograph for permanent implants of palladium-103 seeds,” Int. J. Radiat. Oncol., Biol., Phys. 27, 129136 (1993).
5.
5.U. K. Henschke and P. Ceve, “Dimension averaging a simple method for dosimetry of interstitial implants,” Radiobiol. Radiother. (Berl) 9, 287298 (1968).
6.
6.B. S. Hilaris, D. Nori, and L. L. Anderson, Atlas of Brachytherapy (Macmillan, New York, 1988).
7.
7.H. H. Holm, N. Juul, J. F. Pedersen, H. Hansen, and I. Stroyer, “Transperineal seed implantation in prostatic cancer guided by transrectal ultrasonography,” J. Urol. (Baltimore) 130, 283286 (1983).
8.
8.J. C. Blasko, H. Ragde, and D. Schumacher, “Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance,” Endocurie./Hypertherm. Oncol. 3, 131139 (1987).
9.
9.J. C. Blasko, P. D. Grimm, and H. Ragde, “Brachytherapy and organ preservation in the management of carcinoma of the prostate,” Sem. Radiat. Oncol. 3, 240249 (1993).
10.
10.P. D. Grimm, J. C. Blasko, and H. Radge, “Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer; Technical concepts in planning, operative technique and evaluation,” Atlas Urol. Clin. North Am. 2, 113125 (1994)
11.
11.K. Wallner, S. T. Chiu-Tsao, J. Roy, V. E. Arterbery, W. Whitmore, S. Jain, B. Minsky, P. Russo, and Z. Fuks, “An improved method for computerized tomography-planned transperineal prostate implants,” J. Urol. (Baltimore) 146, 9095 (1991).
12.
12.K. Wallner, J. Roy, M. Zelefsky, Z. Fuks, and L. Harrison, “Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation,” Int. J. Radiat. Oncol., Biol., Phys. 29, 863867 (1994).
13.
13.W. F. Whitmore, B. Hilaris, M. Batata, P. Sogani, H. Herr, and M. Morse, “Interstitial radiation: short-term palliation or curative therapy?Urol. 25, 2429 (1985).
14.
14.J. D. Morton, L. B. Harrison, and R. E. Peschel, “Prostatic cancer therapy: Comparison of external-beam radiation and I-125 seed implantation treatment of stages B and C neoplasms,” Radiology 159, 249252 (1986).
15.
15.J. D. Morton and R. E. Peschel, “Iodine-125 implants versus external beam therapy for stages B, and C prostate cancer,” Int. J. Radiat. Oncol., Biol., Phys. 14, 11531157 (1988).
16.
16.D. A. Kuban, A. M. el-Mahdi, and P. F. Schellhammer, “I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?Cancer (N.Y.) 63, 24152420 (1989).
17.
17.Z. Fuks, S. A. Leibel, K. E. Wallner, C. B. Begg, W. R. Fair, L. L. Anderson, B. S. Hilaris, and W. F. Whitmore, “The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with implantation,” Int. J. Radiat. Oncol., Biol., Phys. 21, 537547 (1991).
18.
18.C. D. Koprowski, K. G. Berkenstock, A. M. Borofski, J. C. Ziegler, D. A. Lightfoot, and L. W. Brady, “External beam irradiation versus implant in the definitive treatment of prostate carcinoma,” Int. J. Radiat. Oncol., Biol., Phys. 21, 955960 (1991).
19.
19.T. P. Weyrich, S. J. Kandzari, and P. R. Jain, “Iodine-125 seed implants for prostatic carcinoma. Five- and ten-year follow-up,” Urol. 41, 122126 (1993).
20.
20.M. J. Zelefsky and W. F. Whitmore, Jr., “Long-term results of retropubic permanent implantation of the prostate for clinically localized prostatic cancer,” J. Urol. (Baltimore) 158, 2329 (1997).
21.
21.R. Nath, K. Roberts, M. Ng, R. Peschel, and Z. Chen, “Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants,” Med. Phys. 25, 22932307 (1998).
22.
22.P. L. Vijverberg, K. H. Kurth, L. E. Blank, N. F. Dabhoiwala, T. H. de Reijke, and K. Koedooder, “Treatment of localized prostatic carcinoma using the transrectal ultrasound guided transperineal implantation technique,” Eur. Urol. 21, 3541 (1992).
23.
23.K. Wallner, J. Roy, M. Zelefsky, Z. Fuks, and L. Harrison, “Short-term freedom from disease progression after I-125 prostate implantation,” Int. J. Radiat. Oncol., Biol., Phys. 30, 405409 (1994).
24.
24.J. C. Blasko, K. Wallner, P. D. Grimm, and H. Ragde, “Prostate specific antigen based disease control following ultrasound guided implantation for stage prostatic carcinoma,” J. Urol. (Baltimore) 154, 10961099 (1995).
25.
25.K. Wallner, J. Roy, and L. Harrison, “Tumor control and morbidity following transperineal iodine-125 implantation for stage prostatic carcinoma,” J. Clin. Oncol. 14, 449453 (1996).
26.
26.B. R. Prestidge, D. C. Hoak, P. D. Grimm, H. Ragde, W. Cavanagh, and J. C. Blasko, “Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer,” Int. J. Radiat. Oncol., Biol., Phys. 37, 3139 (1997).
27.
27.S. H. Stokes, J. D. Real, P. W. Adams, J. C. Clements, S. Wuertzer, and W. Kan, “Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate,” Int. J. Radiat. Oncol., Biol., Phys. 37, 337341 (1997).
28.
28.D. C. Beyer and J. B. Priestley, Jr., “Biochemical disease-free survival following prostate implantation,” Int. J. Radiat. Oncol., Biol., Phys. 37, 559563 (1997).
29.
29.H. Ragde, J. C. Blasko, P. D. Grimm, G. M. Kenny, J. E. Sylvester, D. C. Hoak, K. Landin, and W. Cavanagh, “Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma,” Cancer (N.Y.) 80, 442453 (1997).
30.
30.K. W. Kaye, D. J. Olson, and J. T. Payne, “Detailed preliminary analysis of implantation for localized prostate cancer using percutaneous approach,” J. Urol. (Baltimore) 153, 10201025 (1995).
31.
31.P. Iversen, M. Bak, N. Juul, F. Laursen, H. von der Maase, L. Nielsen, F. Rasmussen, S. Torp-Pedersen, and H. H. Holm, “Ultrasonically guided seed implantation with external radiation in management of localized prostatic carcinoma,” Urol. 34, 181186 (1989).
32.
32.P. Iversen, F. Rasmussen, and H. H. Holm, “Long-term results of ultrasonically guided implantation of seeds combined with external irradiation in localized prostatic cancer,” Scand. J. Urol. Nephrol. Suppl. 138, 109115 (1991).
33.
33.P. L. Vijverberg, L. E. Blank, N. F. Dabhoiwala, T. M. de Reijke, C. Koedooder, A. A. Hart, K. H. Kurth, and D. Gonzalez Gonzalez, “Analysis of biopsy findings and implant quality following ultrasonically-guided implantation for localized prostatic carcinoma,” Br. J. Urol. 72, 470477 (1993).
34.
34.J. B. Priestly and D. C. Beyer, “Guided brachytherapy for treatment of confined prostate cancer,” Urol. 40, 2732 (1992).
35.
35.V. E. Arterbery, K. Wallner, J. Roy, and Z. Fuks, “Short-term morbidity from CT-planned transperineal I-125 prostate implants,” Int. J. Radiat. Oncol., Biol., Phys. 25, 661667 (1993).
36.
36.L. Kleinberg, K. Wallner, J. Roy, M. Zelefsky, V. E. Arterbery, Z. Fuks, and L. Harrison, “Treatment-related symptoms during the first year following transperineal prostate implantation,” Int. J. Radiat. Oncol., Biol., Phys. 28, 985990 (1994).
37.
37.S. Nag, D. D. Scaperoth, R. Badalament, S. A. Hall, and J. Burgers, “Transperineal palladium-103 prostate brachytherapy: analysis of morbidity and seed migration,” Urol. 45, 8792 (1995).
38.
38.K. Wallner, J. Roy, and L. Harrison, “Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 32, 465471 (1995).
39.
39.R. G. Stock, N. N. Stone, and C. Iannuzzi, “Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer,” Int. J. Radiat. Oncol., Biol., Phys. 35, 267272 (1996).
40.
40.J. J. Prete, B. R. Prestidge, W. S. Bice, J. L. Friedland, R. G. Stock, and P. D. Grimm, “A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States,” Int. J. Radiat. Oncol., Biol., Phys. 40, 10011005 (1998).
41.
41.R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Meigooni, “Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Committee Task Group No. 43,” Med. Phys. 22, 209234 (1995).
42.
42.R. Nath, L. L. Anderson, J. Meli, A. J. Olch, J. A. Stitt, and J. F. Williamson, “Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group No. 56,” Med. Phys. 24, 15571598 (1997).
43.
43.J. Desai, R. G. Stock, N. N. Stone, C. Iannuzzi, and J. K. DeWyngaert, “Acute urinary morbidity following I-125 interstitial implantation of the prostate gland,” Radiat. Oncol. Invest. 6, 135141 (1998).
44.
44.E. M. Messing, J. B. Zhang, D. J. Rubens, R. A. Brasacchio, J. G. Strang, A. Soni, P. G. Okunieff, and Y. Yu, “Intraoperative optimized inverse planning for prostate brachytherapy: Early experience,” Int. J. Radiat. Oncol., Biol., Phys. 44, 801808 (1999).
45.
45.N. N. Stone, R. G. Stock, J. K. DeWyngaert, and A. Tabert, “Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry,” Radiat. Oncol. Invest. 3, 185195 (1995).
46.
46.R. G. Stock, N. N. Stone, M. F. Wesson, and J. K. DeWyngaert, “A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation,” Int. J. Radiat. Oncol., Biol., Phys. 32, 219225 (1995).
47.
47.B. R. Prestidge, E. B. Butler, D. Shaw, and Van. McComas, “Ultrasound guided placement of transperineal prostatic afterloading catheters,” Int. J. Radiat. Oncol., Biol., Phys. 28, 263266 (1994).
48.
48.Interstitial Collaborative Working Group (ICWG), Interstitial Brachytherapy: Physical, Biological, and Clinical Considerations, edited by L. L. Anderson et al. (Raven, New York, 1990).
49.
49.D. E. Mellenberg and R. W. Kline, “Verification of manufacturer-supplied and air-kerma strengths,” Med. Phys. 22, 14951497 (1995).
50.
50.V. Feygelman, B. K. Noriega, R. M. Sanders, and J. L. Friedland, “A simple method for verifying activity of iodine-125 seeds in rigid absorbable suture,” Med. Dosim. 21, 261262 (1996).
51.
51.W. M. Butler, A. T. Dorsey, K. R. Nelson, G. M. Merrick, “Quality assurance calibration of I-125 Rapid Strand in a sterile environment,” Int. J. Radiat. Oncol., Biol., Phys. 41, 217222 (1998).
52.
52.W. M. Butler and G. S. Merrick, “I-125 Rapid Strand loading technique,” Radiat. Oncol. Invest. 4, 4849 (1996).
53.
53.V. Feygelman, J. L. Friedland, R. M. Sanders, B. K. Noriega, and J. M. Pow-Sang, “Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles,” Med. Dosim. 21, 109112 (1996).
54.
54.M. Dattoli and K. Wallner, “A simple method to stabilize the prostate during transperineal prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 38, 341342 (1997).
55.
55.K. W. Keye, D. J. Olsen, D. J. Lightner, and J. T. Payne, “Improved technique for prostate seed implantation: combined ultrasound and fluoroscopic guidance,” J. Endourology 6, 6166 (1992).
56.
56.Y. Yu, F. M. Waterman, N. Suntharalingam, and A. Schulsinger, “Limitations of the minimum peripheral dose as a parameter for dose specification in permanent prostate implants,” Int. J. Radiat. Oncol., Biol., Phys. 34, 717725 (1996).
57.
57.P. L. Roberson, V. Narayana, D. L. McShan, R. J. Winfield, and P. W. McLaughlin, “Source placement error for permanent implant of the prostate,” Med. Phys. 24, 251257 (1997).
58.
58.J. N. Roy, C. C. Ling, K. E. Wallner, and L. L. Anderson, “Determining source strength and source distribution for a transperineal prostate implant,” Endocurietherapy/Hyperthermia Oncol. 12, 3541 (1996).
59.
59.F. M. Waterman, N. Yue, S. Reisinger, A. Dicker, and B. W. Corn, “Effect of edema on the post-implant dosimetry of an I-125 prostate implant: A case study,” Int. J. Radiat. Oncol., Biol., Phys. 38, 335339 (1997).
60.
60.F. M. Waterman, N. Yue, B. W. Corn and A. Dicker, “Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition,” Int. J. Radiat. Oncol., Biol., Phys. 41, 10691077 (1998).
61.
61.B. R. Prestidge, W. S. Bice, E. J. Kiefer, and J. J. Prete, “Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 40, 11111115 (1998).
62.
62.J. N. Roy, K. E. Wallner, P. J. Harrington, C. C. Ling, and L. L. Anderson, “A CT-based evaluation method for permanent implants: Application to prostate,” Int. J. Radiat. Oncol., Biol., Phys. 26, 163169 (1993).
63.
63.V. Narayana, P. L. Roberson, A. T. Pu, H. Sandler, R. H. Winfield, and P. W. McLaughlin, “Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants,” Int. J. Radiat. Oncol., Biol., Phys. 37, 11811185 (1997).
64.
64.M. Roach, P. Faillace-Akazawa, C. Malfatti, J. Holland, and H. Hricak, “Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapyInt. J. Radiat. Oncol., Biol., Phys. 35, 10111018 (1996).
65.
65.V. Narayana, P. L. Roberson, R. J. Winfield, and P. W. McLaughlin, “Impact of ultrasound and computed tomography prostate volume registration on evaluation of permanent prostate implants,” Int. J. Radiat. Oncol., Biol., Phys. 39, 341346 (1997).
66.
66.M. A. Moerland, H. K. Wijrdeman, R. Beersma, C. J. Bakker, and J. J. Battermann, “Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging,” Int. J. Radiat. Oncol., Biol., Phys. 37, 927933 (1997).
67.
67.D. F. Dubois, B. R. Prestidge, L. A. Hotchkiss, W. S. Bice, and J. J. Prete, “Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging,” Int. J. Radiat. Oncol., Biol., Phys. 39, 10371041 (1997).
68.
68.J. Willins and K. Wallner, “CT-based dosimetry for transperineal I-125 prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 39, 347353 (1997).
69.
69.W. S. Bice and B. R. Prestidge, “A review of postimplant quality assessment in permanent transperineal interstitial prostate brachytherapy,” J. Brachytherapy Int. 13, 297313 (1997).
70.
70.W. S. Bice, B. R. Prestidge, P. D. Grimm, J. L. Friedland, V. Feygelman, M. Roach, J. J. Prete, D. F. Dubois, and J. C. Blasko, “Centralized multi-institutional post-implant analysis for interstitial prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 41, 921927 (1998).
71.
71.R. G. Stock, N. N. Stone, A. Tabert, C. Iannuzzi, and J. K. DeWyngaert, “A dose-response study for I-125 prostate implants,” Int. J. Radiat. Oncol., Biol., Phys. 41, 101108 (1998).
72.
72.B. S. Hilaris, W. F. Whitmore, Jr., M. A. Batata, and H. Grabstald, “Radiation therapy and pelvic node dissection in the management of cancer of the prostate,” Am. J. Radiol. 121, 832838 (1974).
73.
73.O. Glasser, E. H. Quimby, L. S. Taylor, J. L. Weatherwax, and R. H. Morgan, Physical Foundations of Radiology, 3rd ed. (Harper and Row, New York, 1961).
74.
74.Radium Dosage—the Manchester System, 2nd ed., edited by W. J. Meredith (E. and S Livingstone, Edinburgh, 1967).
75.
75.L. L. Anderson, in Handbook of Interstitial Brachytherapy, edited by B. S. Hilaris (Publishing Sciences Group, Acton, MA, 1975).
76.
76.L. L. Anderson, H. M. Kuan, and I. Y. Ding, in Modern Interstitial and Intracavitary Radiation Cancer Management, edited by F. W. George (Masson, New York, 1981), pp. 9–15.
77.
77.L. L. Anderson and I. Y. Ding, Dosimetric Considerations for Iodine-125, in Afterloading: 20 Years of Experience (Memorial Sloan-Kettering Cancer Center, New York, 1975), pp. 63–72.
78.
78.B. S. Hilaris, J. G. Holt, and J. St. Germain, The Use of Iodine-125 for Interstitial Implants, DHEW Publication (FDA) 76-8022 (U.S. Department of Health, Education and Welfare, Rockville, MD, 1975).
79.
79.V. Krishnaswamy, “Dose distribution around an seed source in tissue,” Radiology 126, 489491 (1978).
80.
80.H. D. Kubo, W. F. Hanson, J. F. Williamson, R. W. Kline, B. M. Coursey, S. M. Seltzer, R. E. Shuping, L. DeWerd, and M. Langton, “Report of the Ad Hoc Committee of the AAPM Radiation Therapy Committee on I-125 sealed source dosimetry,” Int. J. Radiat. Oncol., Biol., Phys. 40, 697702 (1998).
81.
81.C. C. Ling, D. York, I. J. Spiro, D. Kubiatowicz, and D. Bennett, “Physics dosimetry of seeds of a new design for interstitial implant,” Int. J. Radiat. Oncol., Biol., Phys. 9, 17471752 (1983).
82.
82.R. W. Luse, J. Blasko, and P. Grimm, “A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for transperineal prostate seed implants on commercial treatment planning systems,” Int. J. Radiat. Oncol., Biol., Phys. 37, 737741 (1997).
83.
83.W. S. Bice, B. R. Prestidge, J. J. Prete, and D. F. Dubois, “Clinical impact of implementing the recommendations of AAPM Task Group 43 permanent prostate brachytherapy using Int. J. Radiat. Oncol., Biol., Phys. 40, 12371241 (1998).
84.
84.R. Loevinger, “Wide-angle free-air chamber for calibration of low-energy brachytherapy sources,” Med. Phys. 20, 907 (1993).
85.
85.J. F. Williamson, B. M. Coursey, W. F. Hanson, R. Nath, and G. Ibbott, “Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 Interstitial Sources: Dosimetry and calibration changes: Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry,” Med. Phys. 26, 570573 (1998).
86.
86.V. Krishnaswamy, “Dose tables for seed implants,” Radiology 132, 729730 (1979).
87.
87.G. U. V. Rao, P. T. Kan, and R. Howells, “Interstitial volume implants with I-125 seeds,” Int. J. Radiat. Oncol., Biol., Phys. 7, 431438 (1991).
88.
88.F. W. Waterman and K. A. Strubler, “Absorbed dose determination for interstitial boost therapy,” Med. Phys. 10, 155158 (1983).
89.
89.A. Wu, R. D. Zwicker, and E. S. Sternick, “Tumor dose specification of I-125 seed implants,” Med. Phys. 12, 2731 (1985).
90.
90.Y. Yu, “A non-divergent specification of the mean treatment dose in interstitial brachytherapy,” Med. Phys. 23, 905909 (1996).
91.
91.J. E. Dawson, T. Wu, T. Roy, J. Y. Gu, and H. Kim, “Dose effects of seed placement deviations from pre-planned positions in ultrasound guided prostate implants,” Radiother. Oncol. 32, 268270 (1994).
92.
92.Y. Yu and M. C. Schell, “A genetic algorithm for the optimization of prostate implants,” Med. Phys. 23, 20852091 (1996).
93.
93.L. L. Anderson, “A ‘natural’ volume-dose histogram for brachytherapy,” Med. Phys. 13, 898903 (1986).
94.
94.A. van’t Riet, H. J. te Loo, A. F. Ypma, A. C. Mak, F. H. van Slooten, C. J. Hoekstra, and M. C. Stenfert Kroese, “Ultrasonically guided transperineal seed implantation of the prostate: modification of the technique and qualitative assessment of implants,” Int. J. Radiat. Oncol., Biol., Phys. 24, 555558 (1992).
95.
95.R. Nath, A. S. Meigooni, and A. Melillo, “Some treatment planning considerations for and permanent interstitial implants,” Int. J. Radiat. Oncol., Biol., Phys. 28, 971977 (1994).
96.
96.C. C. Ling, J. Roy, N. Sahoo, K. Wallner, and L. L. Anderson, “Quantifying the effect of dose inhomogeneity in brachytherapy: Application to permanent prostatic implant with seeds,” Int. J. Radiat. Oncol., Biol., Phys. 28, 971978 (1994).
97.
97.A. van’t Riet, A. C. Mak, M. A. Moerland, L. H. Elders, and W. van der Zee, “A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate,” Int. J. Radiat. Oncol., Biol., Phys. 37, 731736 (1997).
98.
98.C. B. Saw and N. Suntharalingam, “Quantitative assessment of interstitial implants,” Int. J. Radiat. Oncol., Biol., Phys. 20, 135139 (1991).
99.
99.J. N. Roy, K. E. Wallner, S. T. Chiu-Tsao, L. L. Anderson, and C. C. Ling, “CT-based optimized planning for transperineal prostate planning with customized template,” Int. J. Radiat. Oncol., Biol., Phys. 21, 483489 (1991).
100.
100.V. Narayana, P. L. Roberson, R. J. Winfield, M. L. Kessler, and P. W. McLaughlin, “Optimal placement of radioisotopes for permanent prostate implants,” Radiology 199, 457460 (1996).
101.
101.J. Pouliot, D. Tremblay, J. Ro, and S. Filice, “Optimization of permanent prostate implants using fast simulated annealing,” Int. J. Radiat. Oncol., Biol., Phys. 36, 711720 (1996).
102.
102.Y. Yu, JB Y. Zhang, R. A. Brasacchio, P. G. Okunieff, D. J. Rubens, J. G. Strang, A. Soni, and E. M. Messing, “Automated treatment planning engine for prostate seed implant brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 43, 647652 (1999).
103.
103.Y. Chen, R. E. Stanton, R. J. Holst, C. D. Koprowski, and E. B. Krisch, “Treatment planning for prostate implant with loose seeds,” Med. Phys. 24, 11411145 (1997).
104.
104.S. Kirkpatrick, C. D. Gelatt, and M. P. Vecci, “Optimization by simulated annealing,” Science 220, 671680 (1983).
105.
105.D. E. Goldberg, Genetic Algorithms in Search, Optimization and Machine Learning (Addison-Wesley, Reading, MA, 1989).
106.
106.Y. Yu, “Multiobjective decision theory for computational optimization in radiation therapy,” Med. Phys. 24, 14451454 (1997).
107.
107.M. M. Goodsitt, P. L. Carson, S. Witt, D. L. Hykes, J. M. Kofler, “Real-time B-mode ultrasound quality control test procedures: Report of AAPM Ultrasound Task Group No. 1,” Med. Phys. 25, 13851406 (1998).
108.
108.G. J. Kutcher, L. Coia, M. Gillin, W. F. Hanson, S. Leibel, R. J. Morton, J. R. Palta, J. A. Purdy, L. E. Reinstein, G. K. Svensson, M. Weller, and L. Wingfield, “Comprehensive QA for radiation oncology: Report of AAPM Radiation Therapy Committee Task Group 40,” Med. Phys. 21, 581618 (1994).
109.
109.C. C. Ling, L. L. Anderson, and W. U. Shipley, “Dose inhomogeneity in interstitial implants using seeds,” Int. J. Radiat. Oncol., Biol., Phys. 5, 419425 (1979).
110.
110.G. S. Burns and D. E. Raeside, “The accuracy of single-seed dose superposition for I-125 implants,” Med. Phys. 16, 627631 (1989).
111.
111.A. S. Meigooni, J. A. Meli, and R. Nath, “Interseed effects on dose for brachytherapy implants,” Med. Phys. 19, 385390 (1992).
112.
112.R. G. Dale, “Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides’ with particular reference to iodine-125,” Med. Phys. 10, 176183 (1983).
113.
113.L. Mandell, D. Nori, L. Anderson, M. Belanich, and B. Hilaris, “The effects of permanent I-125 interstitial implantation on cortical boneInt. J. Radiat. Oncol., Biol., Phys. 11, 10291034 (1985).
114.
114.C. C. Ling and E. D. Yorke, “Interface dosimetry for I-125 sources,” Med. Phys. 16, 376381 (1989).
115.
115.A. S. Meigooni and R. Nath, “Tissue inhomogeneity correction for brachytherapy sources in a heterogeneous phantom with cylindrical symmetry,” Med. Phys. 19, 401407 (1992).
116.
116.D. Y. C. Huang, M. C. Schell, K. A. Weaver, and C. C. Ling, “Dose distribution of sources in different tissues,” Med. Phys. 17, 826832 (1990).
117.
117.E. D. Yorke, D. Y. C. Huang, M. C. Schell, R. Wong, and C. C. Ling, “Clinical implication of I-125 dosimetry of bone and bone-soft tissue interfaces,” Int. J. Radiat. Oncol., Biol., Phys. 21, 16131619 (1991).
118.
118.R. G. Dale, “The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy,” Br. J. Radiol. 58, 515528 (1985).
119.
119.R. G. Dale, “Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model,” Br. J. Radiol. 62, 241244 (1989).
120.
120.J. N. Roy, L. L. Anderson, K. E. Wallner, Z. Fuks, and C. C. Ling, “Tumor control probability for brachytherapy: Application to permanent prostate implants,” Radiother. Oncol. 28, 7275 (1993).
121.
121.C. G. Orton, “Time-dose factors (TDF’s) in brachytherapy.Br. J. Radiol. 47, 603607 (1974).
122.
122.C. C. Ling, “Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model.Int. J. Radiat. Oncol., Biol., Phys. 23, 8187 (1992).
123.
123.C. C. Ling, W. X. Li, and L. L. Anderson, “The relative biological effectiveness of I-125 and Pd-103,” Int. J. Radiat. Oncol., Biol., Phys. 32, 373378 (1995).
124.
124.M. L. Freeman, P. Goldhagen, E. Sierra, and E. J. Hall, “Studies with encapsulated sources. II. Determination of the relative biological effectiveness using cultured mammalian cells,” Int. J. Radiat. Oncol., Biol., Phys. 8, 13551361 (1982).
125.
125.M. J. Marchese, E. J. Hall, and B. S. Hilaris, “Encapsulated iodine-125 in radiation oncology. I. Study of the relative biological effectiveness (RBE) using low dose rate irradiation of mammalian cell cultures,” Am. J. Clin. Oncol. 7, 607611 (1984).
126.
126.M. J. Marchese, P. E. Goldhagen, M. Zaider, D. J. Brenner, and E. J. Hall, “The relative biological effectiveness of photon radiation from encapsulated iodine-125, assessed in cells of human origin: I. Normal diploid fibroblasts,” Int. J. Radiat. Oncol., Biol., Phys. 18, 14071413 (1990).
http://aip.metastore.ingenta.com/content/aapm/journal/medphys/26/10/10.1118/1.598721
Loading
/content/aapm/journal/medphys/26/10/10.1118/1.598721
Loading

Data & Media loading...

Loading

Article metrics loading...

/content/aapm/journal/medphys/26/10/10.1118/1.598721
1999-10-01
2015-08-28
Loading

Full text loading...

true
This is a required field
Please enter a valid email address

Oops! This section does not exist...

Use the links on this page to find existing content.

752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd
Scitation: Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64
http://aip.metastore.ingenta.com/content/aapm/journal/medphys/26/10/10.1118/1.598721
10.1118/1.598721
SEARCH_EXPAND_ITEM